Celcuity Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for CELC, updated each market day.
CELC AI Sentiment
AI predicts Celcuity Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Celcuity Inc. Common Stock
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Sector
Exchange
Market Cap
$6,024,683,172
Cap Tier
Employees
155
Headquarters
MINNEAPOLIS, MN
Listed Since
Sept. 20, 2017
Website
CELC Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CELC Volatility
Celcuity Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
